# A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults

> **NCT04900038** · PHASE2 · TERMINATED · sponsor: **ViiV Healthcare** · enrollment: 85 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** GSK3640254
- **DRUG:** Dolutegravir
- **DRUG:** Lamivudine capsules
- **DRUG:** Lamivudine tablets

## Key facts

- **NCT ID:** NCT04900038
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-18
- **Primary completion:** 2022-11-22
- **Final completion:** 2023-05-11
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Company decision to stop compound development. The decision was not based on any safety or efficacy concerns. It reflected the company strategy for portfolio progression.
- **Last updated:** 2023-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04900038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04900038, "A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT04900038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*